ReviewCurrent treatment options in neurology2016
Update on New Daily Persistent Headache.
Review in Current treatment options in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06018025 (New Daily Persistent Headache), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
New Daily Persistent Headache (NDPH): Biomarker Study and Therapy in Children and Adolescents
Who cites it
11 citing papers in PubMed.
- Brain networks activated when aggravating baseline chronic pain of an individual with new daily persistent headache: a case study.BMC neurology · 2025Article
- Hallmarks of primary headache: part 4 - rare headache syndromes.The journal of headache and pain · 2025Review
- Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA.Brain sciences · 2024Article
- New Daily Persistent Headache in the Pediatric and Adolescent Population: An Updated Review.Life (Basel, Switzerland) · 2024Review
- New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and Treatment.Current pain and headache reports · 2023Review
- Which headache disorders can be diagnosed concurrently? An analysis of ICHD3 criteria using prime encoding system.Frontiers in neurology · 2023Article
- Is new daily persistent headache a fallout of somatization? An observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Observational
- Understanding the diagnoses and medical care experience of patients with new daily persistent headache: a qualitative study in Spain.BMJ open · 2021Article
- New Daily Persistent Headache: a Diagnostic and Therapeutic Odyssey.Current neurology and neuroscience reports · 2019Review
- Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.Headache · 2018Article
- Intravenous mannitol in status migrainosus treatment: a clinical case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementNew daily persistent headache (NDPH) is an uncommon and under-recognized primary headache disorder. Clinically, NDPH may resemble migraine or tension-type headache. Unlike migraine or tension-type headaches, however, a distinguishing feature of NDPH is that the majority of patients with NDPH can pinpoint the exact date of onset of symptoms. While cases can arise de novo, in multiple reports, a viral illness precedes the onset of headache. NDPH has two temporal profiles: a self-limited form that resolves spontaneously without treatment and a refractory, persistent form in which headaches continue unabated for years. Diagnosis is predicated on first eliminating secondary mimics via diagnostic imaging and hematological studies. Lumbar puncture should be considered in patients who are refractory to treatment to search for alterations in CSF pressure or for an infectious process. There have been no randomized clinical trials utilizing acute or preventive therapies for NDPH. In clinical practice, treatment is aimed at matching the predominant headache phenotype; nonetheless, most therapies are generally ineffective or only partially effective. Not surprisingly, medication overuse is very common among patients with this disorder and should be identified, although in most patients, eliminating medication overuse does not alter the course of the illness. There have been reports of successful treatment combining doxycycline 100 mg and montelukast 10 mg, dosed BID for 3 months. Anecdotally, in our practice, this combination has occasionally provided good results. Onabotulinum toxin injections are currently under investigation and may provide a potential new effective treatment regimen.
Indexed as
Identifiers
27080086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.